Cryo-Cell International Reports Revenue and Net Income Decline in Q3 2025

Cryo-Cell International, Inc. reported its financial results for the third quarter and nine months ended August 31, 2025, revealing a decline in revenue and net income compared to the same period in the previous year. Total revenue for the three months was $7.83 million, down 3% from $8.07 million in the prior year, while revenue for the nine months decreased to $23.72 million from $23.96 million. The decline in revenue was primarily attributed to a 14% decrease in new domestic cord blood specimens processed, despite a 3% increase in recurring annual storage fee revenue.

The company's net income for the third quarter was $749,408, or $0.09 per share, compared to $1.05 million, or $0.13 per share, in the same quarter last year. For the nine-month period, net income fell to $1.39 million from $2.26 million in the prior year. The decrease in profitability was influenced by increased legal expenses related to ongoing litigation, which rose by $604,000, and a significant drop in public banking revenue, which fell to $128,886 from $205,799.

Operationally, Cryo-Cell's total current assets decreased to $11.67 million from $12.55 million, with cash and cash equivalents dropping to $265,207 from $560,960. The company reported a total of 240,000 cord blood and cord tissue specimens stored, maintaining its position as a leading private cord blood bank. However, the company faced challenges in its public banking segment, which experienced volatility in customer demand, impacting revenue generation.

In terms of strategic developments, Cryo-Cell has been involved in legal proceedings against Duke University regarding a Patent and Technology License Agreement, which has led to a pause in the anticipated opening of the Cryo-Cell Institute for Cellular Therapies. The company has also indicated that it may require additional capital to fund future projects, particularly those related to the Duke License Agreement, which has been a significant focus of its business strategy. Looking ahead, Cryo-Cell anticipates that its cash reserves, marketable securities, and operational cash flows will be sufficient to meet its needs for at least the next 12 months, although the outcome of the Duke dispute remains uncertain and could impact future funding requirements.